文献速递治疗药物监测与药物基因组学

药物基因组学检测与抑郁症状缓解:前瞻性对照临床试验的系统综述与Meta分析

Pharmacogenomic Testing and Depressive Symptom Remission: A Systematic Review and Meta-Analysis of Prospective, Controlled Clinical Trials.
PubMed 文献 · Clin Pharmacol Ther · 2022-10-11

该系统综述与Meta分析纳入13项前瞻性对照临床试验(共4767例重性抑郁障碍患者),评估药物基因组学(PGx)指导抗抑郁治疗与抑郁症状缓解的关联。汇总分析显示,PGx指导组实现缓解的可能性为无指导组的1.41倍(95%CI 1.15-1.74,P=0.001);随机对照试验亚组汇总风险比为1.46(95%CI 1.13-1.88),开放标签试验为1.26(95%CI 0.84-1.88)。结论认为PGx指导抗抑郁治疗与成人MDD抑郁症状缓解存在适度但显著的增加相关。

要点

  • PGx指导抗抑郁治疗使MDD患者缓解可能性提高41%(RR 1.41,95%CI 1.15-1.74)。
  • 随机对照试验亚组RR为1.46(95%CI 1.13-1.88),开放标签试验RR为1.26(95%CI 0.84-1.88)。
  • 试验间PGx检测组合(基因与等位基因)及处方推荐异质性较大,可能影响疗效不确定性。

核心结论

  • PGx指导抗抑郁治疗与成人MDD抑郁症状缓解存在适度但显著的增加相关(汇总RR 1.41,95%CI 1.15-1.74,P=0.001)。
  • 随机对照试验汇总RR为1.46(95%CI 1.13-1.88),开放标签试验汇总RR为1.26(95%CI 0.84-1.88)。

研究设计与样本

  • 系统综述与Meta分析,纳入截至2022年7月12日发表的英文前瞻性对照临床试验。
  • 共分析13项试验、4767例患者,包括10项随机对照试验和3项开放标签试验。
  • 采用随机效应模型估计汇总风险比,并按2020年PRISMA指南进行数据提取与合成,评估每项试验的偏倚风险。

主要发现

  • 接受PGx指导抗抑郁治疗的患者(n=2395)实现缓解的可能性为接受无指导治疗者(n=2372)的1.41倍(95%CI 1.15-1.74,P=0.001)。
  • 随机对照试验汇总风险比为1.46(95%CI 1.13-1.88)。
  • 开放标签试验汇总风险比为1.26(95%CI 0.84-1.88)。

临床怎么用

  • PGx检测可作为临床医生选择抗抑郁药物及确定剂量的参考策略,以辅助个体化治疗。
  • 鉴于开放标签试验汇总结果置信区间跨越无效线,解读PGx指导疗效时需结合试验设计类型。

局限性

  • 试验间PGx检测组合(即检测的基因与等位基因)及伴随的处方推荐存在异质性,增加疗效评估的不确定性。
  • 纳入试验包含开放标签设计,可能引入偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Pharmacogenomic (PGx) testing has emerged as a compelling strategy that clinicians can use to inform antidepressant medication selection and dosing, but the clinical efficacy of this strategy has been questioned. We systematically reviewed and meta-analyzed clinical trials for an association between the use of PGx-guided antidepressant therapy and depressive symptom remission in patients with major depressive disorder (MDD). We included prospective, controlled clinical trials published in English up to July 12, 2022. Data extraction and synthesis adhered to the 2020 Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Each trial was assessed for risk of bias and a random-effects model was used to estimate pooled risk ratios. Thirteen trials comprising 4,767 patients were analyzed, including 10 randomized controlled trials, and three open label trials. Across all included trials, those that received PGx-guided antidepressant therapy (n = 2,395) were 1.41 (95% confidence interval (CI) = 1.15-1.74, P = 0.001) more likely to achieve remission compared with those that received unguided antidepressant therapy (n = 2,372). Pooled risk ratios for randomized controlled trials and open label trials were 1.46 (95% CI: 1.13-1.88) and 1.26 (95% CI = 0.84-1.88), respectively. These results suggest that PGx-guided antidepressant therapy is associated with a modest but significant increase in depressive symptom remission in adults with MDD. Efforts to address the heterogeneity in PGx test composition (i.e., genes and alleles tested) and accompanying prescribing recommendations across trials will likely reduce the uncertainty about the efficacy of PGx-guided antidepressant therapy in the literature.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Brown LC, Stanton JD, Bharthi K, et al. Pharmacogenomic Testing and Depressive Symptom Remission: A Systematic Review and Meta-Analysis of Prospective, Controlled Clinical Trials. Clin Pharmacol Ther. 2022. PMID: 36111494. doi:10.1002/cpt.2748

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。